Copyright © 2002 by the European Society of Cardiology.
Editorials
Pricing a year of life: a necessary exercise in modern health care
Bristol Heart Insititute, University of Bristol, Bristol, U.K.
References
- Brown RE, Henderson RA, Koster D, Hutton J, Simoons ML. Cost effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. Eur Heart J. 2002;23:5058
[Abstract/Free Full Text] - N Engl J Med. 1998;339:436443
[Abstract/Free Full Text] - N Engl J Med. 1998;338:14981505
[Abstract/Free Full Text] - Lancet. 1997;349:14291435[CrossRef][Web of Science][Medline]
- Bell DM. Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. Pharmacotherapy. 1999;19:10861093[Medline]
- Reed SO, Mullins CD, Magder LS. Cost effectiveness of abciximab during routine medical practice. Pharmacoeconomics. 2000;18:265274[CrossRef][Web of Science][Medline]
- Mark DB, Harrington RA, Lincoff AM. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation. 2000;101:366371
[Abstract/Free Full Text] - Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356:916[CrossRef][Web of Science][Medline]
- Cannon CP, Weintraub WS, Demopoulos LA. TACTICS-TIMI18 Investigators. N Engl J Med. 2001;344:18791887
[Abstract/Free Full Text] - Bertrand ME, Simoons ML, Fox KA. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000;21:14061432
[Free Full Text] - Boden WE, McKay RG. Optimal treatment of acute coronary syndromesan evolving strategy. N Engl J Med. 2001;344:19391942
[Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||